Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WMV865. CME/NCPD/AAPA credit will be available until March 25, 2025.  Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Lilly.  Disclosure information is available at the beginning of the video presentation.

Javier Morales, MD, FACP, FACE - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.  Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.  Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.  Faculty/Planner DisclosuresCo-Chair/PlannerAdam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.Speaker  for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.  Co-Chair/PlannerShawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.  Co-Chair/PlannerPeter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.  Co-Chair/PlannerProfessor Dedee Murrell has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.  Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Adam Friedman, MD, FAAD - Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, P

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.  A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.  Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.  Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.  Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.  Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.  For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.  Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World   In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  SupportThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.  Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.  Faculty/Planner DisclosuresChair/PlannerLeonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.Speaker  for Regeneron Pharmaceuticals Inc. and Sanofi.Other Financial or Material Support for Patents and Royalties from Elsevier.  Faculty/PlannerKlaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.  PresenterArzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.Grant/Research Support from Sanofi.Speaker  for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.  Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

Download our free app to listen on your phone